-
Some High Dividend Paying Stocks For A Weak Market (MO, MRK, JNJ, NLY)
Wednesday, March 16, 2011 - 3:59pm | 526Investors are experiencing some volatile times right now, with nearly every headline out of Japan moving the market sharply higher or lower. Dividends are important to juice yields and returns, as well as being an important source of income for many, especially retirees. Here is a list of a few...
-
Technical Updates On First Philippine Holdings Corporation (FPH)
Wednesday, March 16, 2011 - 2:00pm | 883Last January 24, I posted my stock analysis on First Philippine Holdings or FPH in the Philippine Stock Exchange and mentioned that there was symmetrical triangle pattern forming (kindly check here). I was leaning towards a breakout from the triangle rather than a breakdown since...
-
Options Brief: Endo Pharmaceuticals (ENDP)
Wednesday, March 16, 2011 - 11:08am | 105Shares of Endo Pharmaceuticals (NASDAQ: ENDP) are lower on the session by 1.39%, trading at $33.98. Overall call volume is now running at 14.67x the daily average, with 40% of all calls traded being purchases on the offer. 4,049 contracts have traded on the session so far. Endo Pharmaceuticals...
-
Options Brief: Mylan Inc. (MYL)
Wednesday, March 16, 2011 - 11:05am | 83Shares of Mylan Inc. (NYSE: MYL) are lower on the session by 3.37%, trading at $21.06. Overall call volume is now running at 2.21x the daily average, with 35% of all calls traded being purchases on the offer. 3,289 contracts have traded on the session so far. Mylan Inc. is a global...
-
Repros Therapeutics Commences Dosing Third Cohort in Low Dose Proellex Study
Wednesday, March 16, 2011 - 9:31am | 210Repros Therapeutics Inc. (Nasdaq: RPRX)today announced it has commenced dosing the 6 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 3 mg dose. No signals of liver toxicity were detected to date in the...
-
Duncan-Williams Revises CADX Estimates
Wednesday, March 16, 2011 - 8:24am | 183Duncan-Williams reports that, with regard to Cadence Pharmaceuticals Inc. (NASDAQ: CADX), “after reviewing the 10K and speaking with management we have realized that our first year ramp curve is overly aggressive.” “Management indicated that stocking a hospital typically corresponds to a single...
-
Duncan-Williams Maintains Hold Rating On ISPH
Wednesday, March 16, 2011 - 8:08am | 120Duncan-Williams is maintaining its Hold rating on shares of Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH). “We report that the FDA approved an ANDA for generic epinastine hydrochloride (Allergan's Elestat) on March 14,” Duncan-Williams writes. “The generic company receiving the first ANDA approval...
-
UPDATE: Goldman Sachs Raising Price Target On Warner Chilcott Ltd. (WCRX)
Wednesday, March 16, 2011 - 7:40am | 179Goldman Sachs is raising its price target on shares of Warner Chilcott Ltd. (NASDAQ: WCRX) to $26 from $25, and has a Neutral rating on shares. In a note to investors, Goldman writes, "We are increasing our 2011E to 2013E EPS to reflect the recent refinancing of WCRX's term loans and our increased...
-
Alexza Reports Q4 EPS of $0.42
Tuesday, March 15, 2011 - 4:09pm | 106Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for the fiscal quarter and year ended December 31, 2010, and provided a general corporate update. Alexza recorded net income of $25.4 million in the fourth quarter of 2010, while posting a net loss of $1.5 million for...
-
Zings Of The Day (CCME, HPQ, PFE)
Tuesday, March 15, 2011 - 3:56pm | 174China MediaExpress Holdings Inc. (NASDAQ: CCME) announced that Chief Financial Officer Jacky Lam and auditor Deloitte Touche Tohmatsu have resigned, amid allegations that the company is a fraud. I guess sleeping at your desk is the new killing it. Hewlett-Packard Co. (NYSE: HPQ) Chief Executive...
-
Lannett Company Expecting Facility Approval Soon (LCI)
Tuesday, March 15, 2011 - 1:16pm | 140Rumors surfaced on Tuesday that Lannett Company (NYSE: LCI) was very close to receiving FDA approval for its New Drug Application (NDA) for Morphine Sulfate Oral Solution, with some rumors suggesting that Lannetts Cody laboratory facility has been passed by the FDA. Lannett's New Drug Application...
-
AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation
Tuesday, March 15, 2011 - 12:07pm | 115AstraZeneca (NYSE: AZN) today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC). The Phase III clinical programme is designed to...
-
Puts Purchased on Endo Pharmaceuticals Holdings Inc. (ENDP)
Tuesday, March 15, 2011 - 11:36am | 150Shares of Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) are lower on the session by 2.54%, currently trading at $34.31. The stock has been moving largely sideways over the past six months and is currently trading above the 200-day moving average. Options traders are buying puts on the name...
-
Repros Reports Results From Completed 1 mg Dose Cohort in Low Dose Proellex Study
Tuesday, March 15, 2011 - 10:06am | 93Repros Therapeutics Inc. (Nasdaq: RPRX) today announced it has completed its internal review of the results obtained for the 1 mg dose from its low dose study of Proellex®. No signals of liver toxicity or drug related adverse events were detected over the 10 week dosing period. Twelve women were...
-
Citi Maintains Hold Rating On LLY
Tuesday, March 15, 2011 - 8:38am | 198Citi is maintaining its Hold rating on shares of Eli Lilly (NYSE: LLY). “Eli Lilly made an offer to purchase Johnson & Johnson's (NYSE: JNJ) (Janssen) Animal Health Business,” Citi writes. “The Janssen business consists of ~50 products, mostly for swine & poultry, with a geographic presence...